ROR

ROR Related Products (78):

By Effects:	Inhibitors (29) Agonists (19) Antagonists (21) Modulators (4) Degraders (2)

Cat. No.	Product Name	Effect	Purity

HY-133128

FM26	Antagonist
FM26 (compound 25) is a potent and allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists with an IC₅₀ of 264 nM. FM26 has a distinct isoxazole chemotype and effectively reduces IL-17a mRNA production in EL4 cells.

HY-128573

RORγt Inverse agonist 3	Antagonist	99.93%
RORγt Inverse agonist 3 is a potent, selective and orally active RORγ inverse agonist, with EC₅₀s of 0.22 μM and 0.15 μM for hRORγ and RORγt (human IL-17 cells), respectively.

HY-142806

RORγt inverse agonist 26
RORγt inverse agonist 26 is a potent reverse agonist of RORγt. RORγt inverse agonist 26 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 26 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 1) .

HY-111509

TAK-828F	Antagonist
TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC₅₀=1.9 nM, reporter gene IC₅₀=6.1 nM). TAK-828F shows excellent RORγt isoforms selectivity (>5000-fold selectivity against human RORα and RORβ).

HY-115777

ARN-6039	Agonist
ARN-6039 is an orally available inverse agonist of RORγ for autoimmune demyelinating disease.

HY-122737

RORγt Inverse agonist 8	Antagonist
RORγt Inverse agonist 8 is a potent, selective, orally bioavailable RORγt inverse agonist, with an IC₅₀ of 19 nM for human RORγt-LBD.

HY-155542

RORγ antagonist 1	Antagonist
RORγ antagonist 1 (compound 22), a potent betulinic acid derivative, is an antagonist of RORγ (K_D=0.18 μM). RORγ antagonist 1 exhibits anti-proliferative activity in HPAF-II pancreatic cancer xenograft model. RORγ antagonist 1 inhibits RAS/MAPK and AKT/mTORC1 pathway, and induces caspase-dependent apoptosis in pancreatic cancer cells.

HY-RS12126

RORA Human Pre-designed siRNA Set A	Inhibitor
RORA Human Pre-designed siRNA Set A contains three designed siRNAs for RORA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-102075B

TMP780	Antagonist	99.51%
TMP780 is an inverse agonist of RORγt with an IC₅₀ of 13 nM. RORγt is a tractable agent target for the treatment of cutaneous inflammatory disorders.

HY-163612

XY077	Agonist
XY077 (compound 14a) is a RORγ inverse agonist with the IC₅₀ of 0.004 μM. XY077 induces cell apoptosis and shows antiproliferative activity in vivoand in vitro.

HY-142937

RORγt agonist 2	Agonist
RORγt agonist 2 is a potent agonist of RORγt. RORγt agonist 2 promotes the differentiation of Th17 cells and enhances the levels of pro-inflammatory cytokines, thereby increasing the cytotoxicity of lymphocytes. RORγt agonist 2 inhibits the production of regulatory T cells, which suppresses the immune response (extracted from patent WO2021136339A1, compound 17).

HY-142843

RORγt/DHODH-IN-1	Inhibitor
RORγt/DHODH-IN-1 (compound (R)-14d) is a potent and orally active dual RORγt/DHODH inhibitor, with IC₅₀s of 0.083 μM and 0.172 μM, respectively. RORγt/DHODH-IN-1 exhibits remarkable in vivo anti-inflammatory activity.

HY-142935

RORγt modulator 2	Modulator
RORγt modulator 2 (Compound 21) is a modulator of retinoid-related orphan receptor γt (RORγt) with the IC₅₀ of <50 nM. RORγt modulator 2 can be used for the research of RORyt mediated diseases such as, e.g., pain, inflammation, COPD, asthma, rheumatoid arthritis, colitis, multiple sclerosis, psoriasis, neurodegenerative diseases and cancer.

HY-100084

Methyl-3β-hydroxycholenate	Modulator
Methyl-3β-hydroxycholenate is a ROR gamma modulator extracted from patent US20110263046 A1, in figure 2.

HY-142703

RORγt inverse agonist 28	Inhibitor
RORγt inverse agonist 28 is a potent reverse agonist of RORγt. RORγt inverse agonist 28 regulates the differentiation of Th17 cells and inhibits the production of IL-17. RORγt inverse agonist 28 has the potential for the research of inflammation and autoimmune diseases (extracted from patent WO2021228215A1, compound 6) .

HY-142847

RORγt/DHODH-IN-3	Inhibitor
RORγt/DHODH-IN-3 (compound (S)-14d) is a dual RORγt/DHODH inhibitor, with IC₅₀s of 0.098 μM and 0.432 μM, respectively. RORγt/DHODH-IN-3 exhibits remarkable in vivo anti-inflammatory activity.

HY-RS12133

Rorc Mouse Pre-designed siRNA Set A	Inhibitor
Rorc Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rorc gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS12127

Rora Mouse Pre-designed siRNA Set A	Inhibitor
Rora Mouse Pre-designed siRNA Set A contains three designed siRNAs for Rora gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-142834

RORγt/DHODH-IN-2	Inhibitor
RORγt/DHODH-IN-2 (compound 1) is a potent dual RORγt/DHODH inhibitor. RORγt/DHODH-IN-2 can be used for inflammatory bowel disease (IBD) research.

HY-148237

JNJ-54119936	Antagonist
JNJ-54119936 is a novel RORγ (RORc) inverse agonist (K_d=5.3 nM).

Name
Email *

	Sorry, but the email address you supplied was invalid.